217 related articles for article (PubMed ID: 8376766)
41. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
42. Soluble components of Hericium erinaceum induce NK cell activation via production of interleukin-12 in mice splenocytes.
Yim MH; Shin JW; Son JY; Oh SM; Han SH; Cho JH; Cho CK; Yoo HS; Lee YW; Son CG
Acta Pharmacol Sin; 2007 Jun; 28(6):901-7. PubMed ID: 17506950
[TBL] [Abstract][Full Text] [Related]
43. Modulation of interferon-induced NK cells by interleukin 2 and cAMP.
Chun M; Hoffmann MK
Lymphokine Res; 1982; 1(4):91-8. PubMed ID: 6097776
[TBL] [Abstract][Full Text] [Related]
44. Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.
Kovacs EJ; Beckner SK; Longo DL; Varesio L; Young HA
Cancer Res; 1989 Feb; 49(4):940-4. PubMed ID: 2783560
[TBL] [Abstract][Full Text] [Related]
45. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
46. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
Tsutsui H; Nakanishi K; Matsui K; Higashino K; Okamura H; Miyazawa Y; Kaneda K
J Immunol; 1996 Nov; 157(9):3967-73. PubMed ID: 8892629
[TBL] [Abstract][Full Text] [Related]
47. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets.
Lebow LT; Jewett A; Bonavida B
J Immunol; 1993 Jan; 150(1):320-9. PubMed ID: 8417130
[TBL] [Abstract][Full Text] [Related]
48. Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines.
Sun R; Li AL; Wei HM; Tian ZG
Cell Res; 2004 Feb; 14(1):67-73. PubMed ID: 15040892
[TBL] [Abstract][Full Text] [Related]
49. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
50. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
51. Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells.
Fujiwara T; Grimm EA
Cancer Res; 1992 Sep; 52(18):4954-9. PubMed ID: 1387585
[TBL] [Abstract][Full Text] [Related]
52. Enhancement of lymphocyte proliferation and IL-2 receptor expression by a processed form (GM-1/P) of monosialoganglioside GM-1.
Giuffrida A; Morrone S; Gismondi A; Santoni G; Punturieri A; Velotti F; Cavallo G; Tubaro E; Piccoli M; Frati L
Immunopharmacol Immunotoxicol; 1990; 12(4):565-82. PubMed ID: 2092040
[TBL] [Abstract][Full Text] [Related]
53. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
54. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
Donskov F; Basse PH; Hokland M
Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
[TBL] [Abstract][Full Text] [Related]
55. Topology of the loxoribine binding site. Studies with inactive loxoribine analogues.
Goodman MG; Goodman JH
J Immunol; 1994 Nov; 153(9):4081-7. PubMed ID: 7930614
[TBL] [Abstract][Full Text] [Related]
56. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
57. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
Ujházy P; Maccubbin D; Eppolito C; Mihich E; Ehrke MJ
Lymphokine Cytokine Res; 1994 Apr; 13(2):99-106. PubMed ID: 8061121
[TBL] [Abstract][Full Text] [Related]
58. Interleukin-2-induced activation of natural killer activity in spleen cells from old and young mice.
Saxena RK; Saxena QB; Adler WH
Immunology; 1984 Apr; 51(4):719-26. PubMed ID: 6608487
[TBL] [Abstract][Full Text] [Related]
59. Thrombin modulation of natural killer activity in human peripheral lymphocytes.
Naldini A; Carney DH
Cell Immunol; 1996 Aug; 172(1):35-42. PubMed ID: 8806804
[TBL] [Abstract][Full Text] [Related]
60. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
